Seems like a positive announcement.
Quote:
"AdAlta conducted a study of AD-214 administered intravenously at various doses and
dose intervals in the bleomycin mouse model. Treatment with AD-214 at 1-30mg/kg every
second day and 10-30mg/kg every fourth day resulted in a statistically significant reduction
in the Ashcroft Score of bleomycin-treated mice compared with mice receiving bleomycin
alone (Figure 1). In contrast, treatment with two drugs currently approved for IPF –
pirfenidone and nintedanib – did not result in a statistically significant reduction in Ashcroft
score under test conditions."
Looks like we have a clear winner here. Bring on the human trials.
- Forums
- ASX - By Stock
- 1AD
- Ann: AD-214 effective in gold standard pre-clinical animal model
Ann: AD-214 effective in gold standard pre-clinical animal model, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AD (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.5¢ |
Change
-0.001(3.85%) |
Mkt cap ! $13.33M |
Open | High | Low | Value | Volume |
2.5¢ | 2.7¢ | 2.5¢ | $26.44K | 1.028M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 664357 | 2.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.7¢ | 54121 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 395000 | 0.025 |
2 | 664357 | 0.024 |
2 | 320000 | 0.023 |
4 | 355000 | 0.022 |
3 | 1197615 | 0.021 |
Price($) | Vol. | No. |
---|---|---|
0.027 | 54121 | 1 |
0.029 | 92629 | 3 |
0.030 | 810875 | 4 |
0.032 | 230000 | 1 |
0.035 | 138786 | 2 |
Last trade - 11.14am 29/05/2024 (20 minute delay) ? |
|
|||||
Last
2.7¢ |
  |
Change
-0.001 ( 3.85 %) |
|||
Open | High | Low | Volume | ||
2.5¢ | 2.7¢ | 2.5¢ | 103667 | ||
Last updated 10.37am 29/05/2024 ? |
Featured News
1AD (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online